OBJECTIVES: Tobacco use following cancer diagnosis is a serious concern for negative health outcomes. Despite ill-effects of tobacco among cancer patients and negative implications for treatment, many patients continue to use tobacco. Oncologists have a pivotal role in promoting tobacco cessation throughout treatment. This study assessed knowledge, readiness, and willingness to conduct and promote tobacco cessation counseling among a national sample of currently licensed practicing US Oncology providers. METHODS: A brief survey was administered in July 2011 via e-mail (Nϭ3006) and US postal mail (Nϭ1000). Samples were obtained from SK&A Information Services, Inc., which used verified addresses and broadcast e-mail surveys with one follow-up. Response rates were 0.6% for e-mail (Nϭ19) and 9.6% for postal mail (Nϭ96), with a 2.9% overall response rate (Nϭ115). RESULTS: Results showed a majority of oncologists do the following often/almost always with patients: ask about tobacco use (96.6%); document tobacco use (93.1%); discuss tobacco use as a cancer risk factor (87.9%); counsel patients on quitting (72.8%); and assess readiness to quit (68.7%). Findings, however, also reported a majority of oncologists do the following never/rarely with patients: provide information about secondhand tobacco smoke (53.5%); provide information on quitlines (59.7%); provide brochures and self-help guides (64.3%); and follow the 5A's model for tobacco treatment (68.6%). On a scale of 0-10, providers indicated they were generally comfortable providing cessation counseling [meanϭ7.0; SDϭ2.4]; however, providers were less willing to participate in a tobacco cessation training program for assisting patients with quitting [meanϭ5.2; SDϭ3.4]. CONCLUSIONS: Findings suggest oncology providers are asking, documenting use, and counseling patients who continue to use tobacco during treatment. Education targeting providers can increase knowledge and practices related to the 5A's treatment model, promoting quitline and self-help information for patients. Effective strategies increasing provider willingness to attend tobacco treatment training sessions should also be encouraged.
PCN119 CHEMOTHERAPY TREATMENT AND SURVIVAL OUTCOME
Lim YS 1 , Lim GCC 2 1 Ampang Hospital, Ampang, Selangor, Malaysia, 2 Kuala Lumpur Hospital, Kuala Lumpur, Kuala Lumpur, Malaysia OBJECTIVES: The main objective was to determine the chemotherapy treatment and outcome. METHODS: Data was collected from 1 June 2008 till 31 December 2008 in Hospital Kuala Lumpur (HKL) using web-based application. Survival data would be obtained via linkage with Registration Department after four years. Data analysis was with STATA statistical software. RESULTS: The total number of patients was 1192.There were 56% females and the most common age group was 50-59 years. The major ethnic groups were Malay (46.5%), Chinese ( 37.3%) and Indians ( 13.8%). Most patients at the oncology clinic at HKL have good performance status with ECOG 0-1 (61.5%). The most prevalent cancers were breast cancer (24.5%), colorectal cancer( 17.4%), bronchus and lung cancer 8.6%, cervical cancer 6.5% and nasopharyngeal cancer (NPC) 6.2%. Most solid tumours were treated by multimodality. 48.8% received 2 or more modalities . There were 547 patients (45.9%) that received radiotherapy and 32.2% that received chemotherapy. 384 patients were given cytotoxic chemotherapy . Most patients (84,1%) received just one regime. The most common regime was a combination of Fluorouracil, Epirubicin and Cyclophosphamide ie FEC (16.4%.) The most often used cytotoxic drugs used were Fluorouracil (26.3%), Cisplatin (15%) followed by Cyclophosphamide (9.9%), Epirubcin (7.3%), Capecitabine ( 6.4%), Docetaxel (4.2%), Gemcitabine (3.7%). The most often used route of administration was intravenous ( 92.6%) mostly infusion as opposed to bolus. Capecitabine was the cytotoxic dug that was the most widely used in the oral form. CONCLUSIONS: This is only sub-study of a long term research that began in 2008 in HKL.. Patterns in chemotherapy usage would change as new drugs emerged in the Formulary. The database would be sustained as a platform for future researches and for survival analysis. (283 words). 
PCN120 THE IMPACT OF UNIVERSAL HEALTH INSURANCE COVERAGE ON USE OF MEDICINES FOR NON-COMMUNICABLE DISEASES IN THAILAND

OBJECTIVES:
In 2001, Thailand implemented the 30 Baht Scheme, a public insurance scheme that covers the poor and uninsured and pays providers through a capitated payment scheme. Our objective is to evaluate the impact of the 30 Baht Scheme on use of medicines in Thailand for three non-communicable diseases: cancer, cardiovascular disease, and diabetes. METHODS: We used an interrupted time series design to measure the impact of the 30 Baht Scheme on total pharmaceutical market volume and market share. We used IMS Health data on quarterly purchases of medicines from hospital and retail pharmacies from 1998 to 2006. RESULTS: The 30 Baht Scheme was associated with long-term increases in hospital sector sales of medicines for conditions that can be adequately treated in outpatient and primary care settings (e.g., diabetes, high cholesterol and high blood pressure). The policy was associated with no change in sales of medicines for more life-threatening diseases, which are more appropriately treated in secondary or tertiary settings (e.g., myocardial infarction, stroke and cancer). The majority of sales were for essential medicines, yet there were also post-policy increases for non-essential medicines. Immediately following the reform, there was a significant shift in hospital sector market share by licensing status for most classes of medicines. We observed large increases in government-produced products, primarily at the expense of branded generics. CONCLUSIONS: Our results suggest that expanding health insurance coverage with a medicines benefit to the entire Thai population increased the volume of medicine sales in primary care hospitals. Our study, however, also suggests that implementation of the 30 Baht Scheme may have been associated with possibly undesirable effects: increased use of non-essential medicines and decreased use of less expensive generics and medicines in secondary and tertiary settings. Thorough evaluation of desired and undesired effects of universal health insurance programs are urgently needed.
PCN121
EVALUATION OF AROMATASE INHIBITOR UTILIZATION AND FAILURE IN POST-MENOPAUSAL WOMEN WITH ADVANCED ER؉/HER2-BREAST CANCER
Landsman-Blumberg P 1 , Namjoshi M 2 , Thomson E 1 , Johnson W 1 1 Thomson Reuters, Washington, DC, USA, 2 Novartis Oncology US, East Hanover, NJ, USA OBJECTIVES: To compare the demographic, clinical and treatment characteristics of post-menopausal women with advanced ERϩ/HER2-breast cancer (BC) treated with aromatase inhibitors (AI) who experienced 0 or Ն 1 AI failure (AIF). METHODS: Women Ն 55 years old, newly diagnosed with metastatic ERϩ/HER2-BC (index) were identified from the 2006-2010 Thomson Reuters MarketScan databases. Patients in the 6-month pre-or variable post-index periods treated with endocrine (ET: tamoxifen, fulvestrant) or AI (anastrozole, letrozole, or exemestane) therapy (ERϩ) and not with trastuzumab or lapatinib (HER2-), with no pre-index diagnosis of primary cancer other than BC, and post-index treatment with Ն 1 AI were retained. AIF was defined post-index as a switch to an alternative AI, ET, or chemotherapy, or AI discontinuation with no further BC treatment. RESULTS: Among 4274 ERϩ/ HER2-BC patients studied, 61% had Ն 1 AIF (80% had 1 and 20% had 2ϩ AIFs). There was no difference in pre-index AI use (54.4% no AIF, 51.8% AIF; pϭ0.093). At index, AIF patients were more likely to be Medicare-eligible (57% vs. 51%) with liver (7% vs. 4%), lung (10% vs. 8%), bone (56% vs. 48%), and brain (7% vs. 5%) metastases, all pϽ0.03. Mean follow-up days was shorter for AIF patients (486 vs. 522, pϭ0.006). First line AI and ET treatments were respectively 95% and 5% for AIF and 97% and 3% for no AIF patients. The most common first line therapy was anastrazole (49% A229 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 -A 2 5 6
